Abstract We report a method to measure in vivo turnover of four proteins from sequential tracheal aspirates obtained from human newborn infants with respiratory distress syndrome using targeted proteomics. We detected enrichment for all targeted proteins approximately 3 h from the start of infusion of [5, 5, H 3 ] leucine, secretion times that varied from 1.2 to 2.5 h, and half lives that ranged between 10 and 21 h. Complement factor B, a component of the alternative pathway of complement activation, had an approximately twofold-longer half-life than the other three proteins. In addition, the kinetics of mature and carboxy-terminal tryptic peptides from the same protein (surfactant protein B) were not statistically different (p00.49).
Introduction
Mass spectrometry has become an indispensible tool for addressing complex biological problems in the multifaceted rapidly expanding field of proteomics. Common problems addressed by mass spectrometry include determination of primary sequences of proteins, identification of sites of post translational modifications, quantification of proteins across different physiological states, and evaluation of proteinprotein interactions. Comparative studies of specific disease states have focused on differences in the presence, modification, and/or abundance of proteins at a single time point.
Michael S. Bereman is currently in the MacCoss Laboratory in the department of Genome Sciences at the University of Washington. He was awarded a NIH Genome training fellowship in 2010 to study the genetic regulators of surfactant metabolism that lead to neonatal respiratory distress syndrome. His work focuses on the development of mass spectrometric methods to investigate protein turnover using both in vivo and in vitro models. His goal is to discover protein kinetic characteristics that are associated with disease acuity and progression-ultimately allowing the elucidation of therapeutic targets.
Although these studies can be informative, a single time point provides only a "static snapshot" of protein abundance in a disease state. Multiple factors that alter protein synthesis or degradation including developmental, genetic, and environmental factors (e.g., diet, exercise, smoking) can change protein abundance. While longitudinal sampling and controlled systems [1, 2] can mitigate protein variability in comparative studies, these strategies do not address measurement of the "missing dimension in proteomics [3] ," the rate of protein synthesis and degradation (i.e., protein turnover). Protein turnover can be used to characterize both normal physiology and disease states [4] [5] [6] . In addition, the determination of differential kinetics between diseased and control would be helpful in the discovery of therapeutic and diagnostic targets and monitoring treatment efficacy. Furthermore, protein turnover data might offer new insights into the discrepancies observed between proteome and transcriptome data [7, 8] .
Traditionally, protein turnover is measured by enrichment of a labeled tracer with gas chromatography/mass spectrometry after infusion of a stable isotopically labeled amino acid, isolation of the proteins of interest from a complex biological fluid, hydrolysis and derivatization [9] [10] [11] . However, this method is limited by low throughput [12] and variable efficacy of protein isolation which may reduce accuracy and permit analysis of only a single, abundant protein. Recently, studies have used SIL tracers and proteomics to determine comprehensive protein turnover. These experiments have focused on in vitro studies [3, 13] or animal models for in vivo studies (e.g., mice [14, 15] , chicken [16] ). In all studies, the relative isotope abundance (RIA), a measure of enrichment of the tracer, was relatively high (>30 %). To permit comprehensive concurrent assessment of turnover of multiple proteins for both systems biology studies and statistical evaluation, new methods to measure proteins with low levels of enrichment must be developed.
In this report, we extend a previous study [17] to demonstrate the ability to measure low levels of enrichments (RIA01-4 %) and calculate kinetic parameters for multiple proteins in tracheal aspirates from human neonates using selected reaction monitoring mass spectrometry preceded by solid-phase extraction to remove phospholipids. We chose four proteins, surfactant protein B, prosaposin, complement factor B, and lactotransferrin. We could reproducibly measure enrichments as low as 1 % from proteotypic peptides from each protein. Half lives were similar between prosaposin, surfactant protein B, and lactotransferrin (10-12 h); however, complement factor B had a half-life of 21 h. This longer half-life suggests an alternate degradation pathway. In addition, we demonstrate that the kinetics of two different peptides from mature and carboxy-terminal surfactant protein B are indistinguishable.
Methods

Materials
Formic acid, ammonium bicarbonate, DTT, and iodoacetamide, were obtained from Sigma Aldrich (St. Louis, MO). Proteomics grade trypsin was purchased from Promega (Madison, WI). HPLC grade acetonitrile was from Burdick & Jackson (Muskegon, MI).
Infusion protocol
The protocol for intravenous infusion of deuterated leucine has been described in detail elsewhere [17] . In brief, each infant received a 5-min priming dose of 18 μmol/kg followed by a 6-h continuous infusion of 18 μmol/kg/h of [5,5,5-2 H 3 ] leucine. Samples were collected via routine airway suctioning of the endotracheal tube after instillation of 0.5 mL of normal saline and aspiration into a sterile trap. Time points were collected every 3-6 h over a 5-day period and stored at −80°C until analysis. All protocols for the sample collection, measurements and analysis were approved by Institutional Review Boards at both Washington University and the University of Washington, and parents of all infants provided informed consent for their infants to participate.
Sample preparation
Using a Bradford assay, we measured total protein concentrations in tracheal aspirate samples and discarded samples with protein concentrations <150 μg/mL due to difficulty in obtaining adequate signal (6 of 77 samples). For sample preparation, 100 μL of aspirate was added to 100 μL of 50 mM ammonium bicarbonate (pH07.8) with 0.2 % (w/w) PPS silent surfactant (Protein Discovery Inc, Knoxville, TN). The mixture was incubated at 100°C for 5 min. DTT was added to a final concentration of 5 mM and the mixture was incubated at 60°C for 30 min to reduce disulfide bonds. Alkylation of free cysteines was performed by the addition of iodoacetamide (15 mM), and the mixture was then incubated at RT in the dark for 30 min. Finally, 10 μg of trypsin was added to the mixture and the sample was digested for 2 h at 37°C. After digestion, 10 μL of 5 M HCl was added to each sample.
Prior to LC-MS analysis, aspirate samples were subjected to solid-phase extractions using a mixed-mode Oasis MCX cartridge (Product # 186000256 Waters Corporation, Boston, MA). Cartridges were conditioned with the buffers in the following order: (1) 1 mL of 100 % methanol; (2) 1 mL of 3/97 ammonium hydroxide/water; (3) 2 mL of 100 % methanol; (4) 3 mL of 0.1 % formic acid in water. Samples were loaded on column and washed with 1 mL of 0.1 % formic acid in water. Following removal of highly hydrophobic species (e.g., negatively charged lipids) with 0.1 % formic acid in methanol, peptides were eluted with 1 mL of 3/97 ammonium hydroxide/methanol. The eluent was then lyophilized in vacuo at 37°C and reconstituted in 50 μL water/acetonitrile (98/2) with 0.1 % formic acid. We found this method critical for removing the large amounts of phospholipids that were present in the aspirate samples which are detrimental to the nanoflow LC-SRM-MS method.
Nano-flow LC-SRM-MS
A 2-μL aliquot of the reconstituted sample (∼1-3 μg of protein) was flushed at a flow rate of 2 μL/min onto a 3-cm trap packed in-house with C12 4 μm (Phenomenex, Torrance, CA, USA) stationary phase. After approximately ten trap-volume washes, the ten-port valve switched and the gradient and data collection commenced. Buffers A and B were 99.9/0.1 water/formic acid and 99.9/0.1 acetonitrile/ formic acid, respectively. The gradient ramped from 3 % B at 3 min to 32 % B at 50 min, and then increased to 80 % B and held constant for 5 min. Initial conditions 97 % A were restored for the final 14 min of the run. Total analytical run time was 70 min. For selected reaction monitoring mass spectrometry (SRM-MS), a ThermoFisher Vantage (San Jose, CA) was used with Q1 set to a resolution of 0.2m/z and Q3 set to a resolution of 0.7m/z. Three transitions were monitored for each peptide and each sample was measured in duplicate.
Method development
Protein sequences in fasta format were imported into an inhouse developed software program called Skyline [18] . Skyline performed an in silico tryptic digestion of all proteins, and peptides were filtered for uniqueness in Skyline by searching the NCBI Human Proteome Database. Unique peptides between 8 and 25 amino acids in length were retained. All proteotypic peptides that contained only a single leucine were monitored and the data was then exported back into Skyline [18] where a single peptide was chosen as a proxy for each protein. For SP-B, the kinetics of two peptides from either the C-terminus or mature forms were evaluated. This final method was then exported directly from Skyline and samples were analyzed with a dwell time of 100 ms. These experiments enabled the determination of the best ionizing leucine containing peptide for maximum sensitivity for each protein.
Kinetic calculations
Raw files were exported back into Skyline for data analysis. The isotope ratio of each peptide was calculated by integrating the area of the M+3 isotope peak and dividing that by the area of the M+0 peak. This integration and ratio calculation were performed automatically in Skyline. For each infant, a time point prior to infusion of deuterated leucine (i.e., T00) was analyzed. The isotope ratio was then converted to a measure of the enrichment by subtracting the isotope ratio at T00 (R 0 ) from the ratio at T0t (R t ). This calculation of the tracer-to-tracee ratio (R t −R 0 ) corrected for endogenous signal in the M+3 channel.
The delay between the start of the infusion and the appearance of the label in the peptide, known as the secretion time (T s ), was calculated by fitting a regression line to the linear part of the synthesis curve and extrapolating it to baseline enrichment [19] . Secretion time represents the time required for d 3 -leucine transport from the blood stream into the lung cells, incorporation of label into proteins, and secretion of labeled peptides into the alveolar lumen of the lung. Fractional catabolic rates (FCR) were calculated for each peptide by taking the slope from the linear regression after natural logarithmic transformation of the clearance trend in each enrichment curve [20] . Fractional synthetic rates were not reported due to the need to accurately determine the amount of [5,5,5-2 H 3 ] leucine in the lung cells. However, if one assumes steady state (i.e., protein abundance does not change) than the FSR is equivalent to the FCR. Half lives were calculated by taking the natural log of 2 divided by FCR [17, 20] .
Results and discussion
Measuring kinetics of multiple proteins Table 1 displays the peptides monitored from each of the four proteins. We chose these proteins based on the detectability of a tryptic peptide containing a single leucine and the biological significance in human infants with respiratory distress syndrome. The ∼10 kb surfactant protein B gene (SFTPB) encodes a 381 amino acid pre-proprotein that is sequentially proteolytically cleaved at amino and carboxy termini and glycosylated in pulmonary alveolar type 2 cells to yield the highly hydrophobic, 8.6 kDa mature protein. Surfactant protein B is structurally homologous to the saposin family of proteins [21] and is critical for surfactant function and homeostasis [22] [23] [24] [25] [26] . Infants with rare, recessive, loss of function SFTPB mutations develop lethal respiratory distress syndrome due to surfactant deficiency and survive only with lung transplantation [27] . Complement factor B is also expressed by alveolar type 2 cells [28] , is an essential component in the alternative pathway of complement activation, and contributes to regulation of airway inflammation [29] . Its abundance has been reported to be lower in infants with respiratory distress syndrome compared to controls [30] . Prosaposin is a multifunctional protein and precursor to saposins A, B, C, and D which are involved in the degradation of sphingolipids [31] . [32, 33] Lactotransferrin is an 80-kDa glycoprotein [34] commonly found in various fluids including milk, saliva, and nasal secretions [35] . It is part of the innate human defense system where its capacity to sequester iron provides antibacterial activity-particularly in the mucus of human infants [34] . H 3 ] leucine ended after 6 h similar enrichment curves were seen for the four proteins with the time from baseline to peak enrichment and back all occurring in less than 48 h. It is important to note that in some cases, we observed a secondary uptake after initial degradation (Fig. 1b and c) . This observation could be attributed to recycling of the labeled amino acid [36] as degradation of labeled proteins provides a minimal increase in the labeled amino acid precursor pool. This increase can then be detected in the enrichment curve as the label is reincorporated into newly synthesized proteins. Table 2 summarizes the secretion time, rate constant, and calculated half live for each protein. Secretion times (T s ) varied between 1.2 and 2.5 h consistent with a similar secretion pathway for the four proteins. Comparable half lives for surfactant protein B, prosaposin, and complement factor B suggest a similar degradation mechanism. However, we found that complement factor B had approximately twofold-longer half-life than the other proteins. For some infants, data quality did not permit confident calculation of kinetic parameters. Specifically, low overall signal intensity and low levels of enrichment compromised prosaposin kinetic parameters for four out of the six infants in the study.
Comparison of different peptides from surfactant protein B
When proteins exist in multiple isoforms or the peptide measured does not reside in the functional domain of the protein, using a single peptide as a proxy for the metabolism of the functional protein may be misleading. In this study and in a previous study [17] , the most abundant and reproducible peptide for surfactant protein B resides on the carboxy-terminus of the proprotein [37] (Fig. 2a) . As a result, these studies measure the turnover of a surfactant protein B peptide that may not accurately reflect kinetics of mature surfactant protein B. In addition, via a combination of western blot analysis and protein-cleavage isotope dilution mass spectrometry, we have confirmed multiple isoforms of SP-B in tracheal aspirates from infants [17, 38] .
To compare kinetics of different surfactant protein B peptides, we measured the enrichment of both the carboxyterminus peptide and a peptide from the mature form (Fig. 2a) of the protein in a subset of infants (n 04). Figure 2b displays a scatter-plot of the enrichment values from these two surfactant protein B peptides. Overall, the enrichment curves look similar as the two lines represent a locally weighted scatter-plot smoothing regression plotted through each respective data set. Using a paired t test for differences in means of the half lives calculated from each individual curve for the two different peptides, we found no statistical difference (p00.49). The indistinguishable kinetics of these two peptides suggest that either the main isoform present in these infants is a combination of the mature and carboxy-terminal peptides or that various isoforms have similar turnover rates.
Conclusion
We have detailed a method to measure the kinetics of multiple proteins in human infants with low levels of enrichment using targeted proteomics. While similar secretion times were observed in all four proteins, one (complement factor B) had twice the half-life of the other three proteins. The similarity in kinetics of a carboxy-terminus peptide and a mature peptide from surfactant protein B suggests tight kinetic linkage of these isoforms or a combination of both peptides in measurement of enrichment of the major surfactant protein B isoform. Future studies will look at correlations between clinical and kinetic turnover data to identify peptide kinetic characteristics associated with disease acuity, progression, and response to therapeutic interventions.
